Target intelligence / Profile preview

Protein Lin28 homolog B (LIN28B)

Target
LIN28B
Molecular classification
RNA-binding protein, Other
01

Overview

Protein Lin28 homolog B (LIN28B) is an evolutionarily conserved RNA-binding protein that plays a critical role in developmental timing, pluripotency, and oncogenesis. It primarily functions as a post-transcriptional repressor of the let-7 family of microRNAs by binding to their primary (pri-let-7) and precursor (pre-let-7) transcripts, thereby blocking their maturation. Because let-7 microRNAs act as key tumor suppressors that target major oncogenes such as MYC, RAS, and HMGA2, the overexpression of LIN28B leads to let-7 depletion and drives cell proliferation, metastasis, and cancer stemness. LIN28B is highly upregulated in various malignancies, including hepatocellular carcinoma, neuroblastoma, triple-negative breast cancer, and therapy-resistant prostate cancer, making it an attractive therapeutic target. Although historically considered 'undruggable' due to its lack of conventional small-molecule binding pockets, recent drug discovery efforts have identified several preclinical small-molecule inhibitors (such as Compound 1632, LI71, and ponicidin) and PROTACs that disrupt the LIN28B/let-7 interaction or induce LIN28B degradation to restore tumor-suppressive let-7 levels.

Other names
Lin-28 homolog BProtein lin-28 homolog BLIN28BLin-28B
02

Mechanism of action

Inhibition of LIN28B binding to let-7 precursor microRNAs (pre-let-7/pri-let-7), thereby restoring let-7 maturation and suppressing downstream oncogenes (e.g., MYC, RAS, HMGA2, SOX2). Some compounds or PROTACs also induce LIN28B protein degradation.

03

Biological functions

RNA-mediated gene silencingCell proliferationCell cycleOther
04

Disease associations

CancerOther
05

Safety considerations

Potential toxicity in normal stem cells or germ cells due to disruption of physiological pluripotency and developmental pathwaysDisruption of normal tissue regeneration and metabolic homeostasisOff-target effects on other RNA-binding proteins with similar domains, such as LIN28A or YBX1Systemic immune or inflammatory toxicities associated with RNA-targeted therapies
06

Interacting drugs

Compound 1632

11 more in the full profile.

07

Biomarkers

LIN28B expressionlet-7 microRNA levelsHMGA2 expressionSOX2 expressionMYC expressionrs314280 polymorphism

Beyond the preview

Go deeper on Protein Lin28 homolog B (LIN28B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein Lin28 homolog B (LIN28B).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call